Actavis extends agreement to market, distribute generic Concerta

DUBLIN — Actavis has reached an agreement with Janssen Pharmaceuticals to continue supplying the authorized generic version of Janssen's Concerta (methylphenidate hydrochloride extended-release tablets), the company announced.



Under the terms of the agreement, Janssen Pharmaceuticals will continue to manufacture and supply Actavis with all dosage strengths of the generic drug, and Actavis will continue to market and distribute the drug in the United States. This agreement runs until Dec. 31, 2017.



Concerta is indicated for the treatment of attention deficit hyperactivty disorder in children ages 6 years to 17 years and in adults ages 18 years to 65 years, as part of a total treatment program. The drug had U.S. brand and generic sales of $1.4 billion for the 12 months ended Feb. 28, according to IMS Health.